This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.
- Investigator
- Hans H Shuhaiber
- Status
- Accepting Candidates
- Ages
- 12 Years - N/A
- Sexes
- All